Given that a relatively minor amendment to the Hatch-Waxman Act could give the FDA the authority it requires to assess patents submitted for Orange Book listing and to reject inappropriate patents ...

Yesterday, the Federal Trade Commission (FTC) sent a series of seven warning letters to several pharmaceutical companies renewing the agency’s challenge to dozens of patent listings in the U.S ...

Improper Orange Book listings may have distorted the pharma market for decades, the policy statement said. An FTC review of the potential effects of improper Orange Book listings was included in a ...

About Evoke Pharma, Inc. Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat ...

Evoke Pharma shares surged after the company received a notice of allowance for a U.S. patent application for Gimoti extending Orange Book listings to 2036.

During the past two years, we have reported on actions regarding the listing of certain patents in the U.S. Food and Drug Administration’s (FDA) Orange Book for drug/device products where the ...